Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by JohnEnglishon Apr 04, 2015 6:41pm
97 Views
Post# 23597585

RE:RE:Re:test studies

RE:RE:Re:test studiesI wasn't bashing, I just pointed out that the preliminary studies were being held prior to the phase 2 tirals as some seemed to be suggesting that phase 2 was gong ahead. My understnding from the M|Partners report is that first they'll do the validating studies and then, depending on their outcome, they'll run the phase 2 trials. 

My, hypothetical, question was what happens if the validating studies show that there isn't any dramatic benefit to ATB-346 at the lower dosage? Anyway, we'l have to wait and see.

To whoever said that ATB-346 is just naproxen, that's true but GI tract bleeding related to pain killer medication is one of the biggest killers and causes of complications to people post surgery. So something like ATB-346 that is just as effective as naproxen but without the GI bleeding issue would be a huge deal to doctors and sugeons all over the world.
Bullboard Posts